BIOGRAPHICAL SKETCH
Dr. XIFENG WU
|
|
NAME XIFENG WU |
POSITION
TITLE ASSOCIATE PROFESSOR |
EDUCATION/TRAINING
(Begin with baccalaureate or other
initial professional education, such as nursing, and include postdoctoral
training.)
INSTITUTION AND LOCATION |
DEGREE (if applicable) |
YEAR(s) |
FIELD OF STUDY |
Shanghai
Medical University, China
Zhejiang Medical University, China UT
School of Public Health, Houston, TX |
M.D. M.S. Ph.D. |
1984 1987 1994 |
Medicine Occupational
Health Epidemiology |
Professional Experience:
1987 - 1990 Research
Associate, Institute of Industrial Hygiene and Occupational Diseases, Zhejiang
Academy
of Medical Science, China
1990 - 1991 Post
Doctoral Fellow, National Laboratory of Industrial Environment and Risk
Analysis
(INERIS),
Division of Occupational Health, France
1991 - 1994 Graduate
Research Assistant, The University of Texas M.D. Anderson Cancer Center,
Department
of Cell Biology, Houston, TX
1995
- 1995 Research Associate of
Epidemiology, The University of Texas M.D. Anderson Cancer Center, Department
of Epidemiology, Houston, TX
1995 - 2000 Assistant Professor of Epidemiology, The
University of Texas M.D. Anderson Cancer Center, Department of Epidemiology,
Houston, TX
1995 - 2000 Assistant Professor of Biological
Science, The University of Texas School of Public Health, Houston, TX
2000 - present Associate Professor of Epidemiology, UT
M.D. Anderson Cancer Center, Department of Epidemiology
2001 - present Associate Professor of Epidemiology, UT
Graduate School of Biomedical Sciences
2000 - present Associate
Professor of Epidemiology, The University of Texas School of Public Health,
Houston, TX
Honors and
Awards:
1989
Zhejiang
Scientific and Technologic Advance Award
1993 D. Jack Kilian Scholarship, The
University of Texas School of Public Health, Houston, TX
1995
Richard C. Devereaux Award in Lung Cancer
Prevention, Cancer Research Foundation of America
2002 Faculty Scholar Award, The University of Texas M.D. Anderson Cancer Center,Houston, TX
Selected Publications: (From a total of
73 peer reviewed publications, 3 invited publication and 7 book chapters)
Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, WuX.
Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with
genetic predisposition to bladder cancer.
Gene Chromosome & Cancer
(in press).
Gorlova O, Amos
C, Henschke C, Lei L, Spitz M, Wei Q, Wu
X, Kimmel M. Genetic susceptibility for lung cancer: Interactions with
gender and smoking history and impact on early detection policies. Human Heredity (in press).
Zheng L, Wang Y, Schabath MB,
Grossman HB, Wu X.
Sulphotransferase (SULT) 1A1 polymorphism and bladder cancer risk: A
case-control study. Cancer Letters (in press).
Wang Y, Liang D, Spitz MR,
Zhang K, Dong Q, Amos CI, Wu X. XRCC3 genetic polymorphism, smoking, and
lung cancer risk in minorities. Cancer (in press).
Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong
WK, Spitz MR. Telomere Dysfunction: A Cancer Predisposition Factor? Journal
of the National Cancer Institute 2003; 95(16):1211-8.
Wu X,
Tortolero GL, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of
insulin-like growth factor-I and risk of squamous intraepithelial lesions of
the cervix. Clinical Cancer Research 2003; 9 (9):3356-61.
Wang
Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu
X. From genotype to
phenotype: Correlating XRCC1 polymorphisms with mutagen
sensitibity. DNA Repair 2003; 2(8):901-8.
Do
KA, Johnson MM, Doherty DA, Lee JJ, Wu
XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR. Second primary tumors in
patients with upper aerodigestive tract cancers: joint effects of smoking and
alcohol (United States). Cancer Causes Control 2003; 14(2):131-8.
Park SJ, Zhao H,
Spitz MR, Grossman HB, Wu X. An
association between NQO1 genetic polymorphism and risk of bladder cancer.
Mutation Research 2003; 536(1-2):131-7.
Hazra A,
Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X. Death receptor 4 and bladder cancer risk. Cancer Research 2003; 63(6):1157-9.
Wu X, Zhao H, Wei Q, Amos CI, Zhang K, Guo Z, Qiao
Y, Hong WK, Spitz MR. XPA polymorphism associated with reduced lung cancer risk
and a modulating effect on nucleotide excision repair capacity. Carcinogenesis
2003; 24(3):505-9.
Wang Y, Spitz MR, Schabath MB, Hong WK, Wu X. Association between glutathione S-transferase p1 polymorphisms and
lung cancer risk in Caucasians: a case-control study. Lung Cancer 2003;
40(1):25-32.
Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney
CP, Zeng P, Wu X. Genetic instability in bladder cancer
assessed by the comet assay. Journal of
the National Cancer Institute 2003; 95(7):540-7.
Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K,
Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3 and
their association with bladder cancer risk.
Journal of Urology 2003; 169(2):714-7.
Zhang H, Spitz MR, Tomlinson
GE, Schabath MB, Minna JD, Wu X.
Modification of lung cancer susceptibility by green tea extract as
measured by the comet assay. Cancer
Detection and Prevention 2002; 26:411-8.
Spitz MR, Barnett MJ, Goodman GE,
Thornquist MD, Wu X, Pollak M.
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk
of lung cancer: A case-control study nested in the β-Carotene and retinol
efficacy trial cohort. Cancer Epidemiology Biomarkers and Prevention 2002;
11:1413-8.
Zhu Y, Spitz MR, Strom S, Tomlinson GE, Minna JD, Wu
X. A case-control analysis of
lymphocytic chromosome 9 aberrations in lung cancer. International Journal of Cancer 2002; 102: 536-40.
Zhu Y, Spitz MR, Hsu TC, Wu
X. Genetic instability of specific
chromosomes associated with a family history of cancer. Cancer Genetics and
Cytogenetics 2002; 136(1):73-7.
Chang S, Wu X., Yu
H., Spitz MR. Plasma concentrations of insulin-like growth factors among
healthy adult men and postmenopausal women: associations with body composition,
lifestyle, and reproductive factors. Cancer Epidemiology Biomarkers and Prevention 2002; 11:758-66.
Zhu Y, Spitz MR, Zheng Y, Hong WK, Wu X.
BPDE-induced lymphocytic 3p21.3 aberrations may predict head and neck
carcinoma. Cancer 2002; 95(3):563-8.
Schabath MB, Spitz MR, Delclos GL, Gunn GB,
Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking,
myeloperoxidase (MPO)
genotypes, and lung cancer risk. American Journal of Industrial Medicine 2002;
42(1):29-37.
Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds
WF, Gunn GB, Whitehead LW, Wu X. A myeloperoxidase polymorphism associated with
reduced risk of lung cancer. Lung Cancer 2002; 37:35-40.
Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M,
Hong WK, Spitz MR. Chromosome instability in lymphocytes: A potential indicator
of predisposition to oral premalignant lesions. Cancer Research 2002;
62(10):2813-8.
Wu X, Zhao H, Amos
CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 genotypes and
haplotypes associated with lung cancer susceptibility and ethnicity. Journal of
the National Cancer Institute 2002; 94(9):681-90.
Zhao H, Spitz MR, Gwyn KM, Wu X. Microsomal epoxide hydrolase polymorphisms
and lung cancer risk in non-hispanic Whites. Molecular Carcinogenesis 2002;
33(2):99-104.
Wang Y, Spitz MR, Tsou A, Zhang K, Makan N, Wu X.
Sulphotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung
cancer: Aa case-control analysis. Lung Cancer 2002; 35(2):137-42.
Buchholz TA, Wu X,
Hussain A, Tucker SL, Mills GB, Haffty B, Bergh S, Story M, Geara FB, Brock WA.
Evidence of haplotype insufficiency in human cells containing a germline
mutation in BRCA1 or BRCA2. International Journal of Cancer 2002; 97(5):557-61.
Zhu Y, Spitz MR, Lei L, Wu X. A single nucleotide polymorphism in the
matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer
Research 2001; 61(21):7825-9.
Zhao H, Spitz MR, Tomlinson GE, Zhang H, Minna JD,
Wu X. g-Radiation-induced G2 delay,
apoptosis, and p53 Response as potential susceptibility markers for lung
cancer. Cancer Research 2001;
61(21):7819-24.
Wu X, Gwyn K, Amos CI, Makan N, Hong WK, Spitz MR.
The association of microsomal epoxide hydrolase polymorphisms and lung cancer
risk in African-Americans and Mexican-Americans. Carcinogenesis 2001;
22(6):923-8.
Spitz MR, Wu X, Wang Y, Wang L, Shete S, Amos CI,
Guo Z, Lei L, Mohrenweiser H, Wei Q.
Modulation of nucleotide excision repair capacity by XPD polymorphisms
in lung cancer patients. Cancer Research 2001; 61(4):1354-7.
Buchholz TA, Wu X. Radiation-induced chromatid
breaks as a predictor of breast Cancer Risk. International Journal Of Radiation Oncology, Biology, Physics 2001; 49(2):533-7.
de Andrade M, Spitz MR, Wu X, Liang JC, Strom SS.
Statistical models for analysis of cytogenetic biomarkers. Journal of
Investigative Medicine 2000; 48(4):281-6.
Wu X, Hudmon KS, Detry MA, Chamberlain RM, Spitz MR.
D2 dopamine receptor gene polymorphisms among African-Americans and
Mexican-Americans: a lung cancer case-control study. Cancer Epidemiology,
Biomarkers and Prevention 2000; 9:1021-6.
Spitz MR, Duphorne CM, Detry MA, Pillow PC, Amos CI,
Lei L, de Andrade M, Gu X, Hong WK, Wu X.
Dietary intake of isothiocyanates: evidence of a joint effect with
glutathione S-transferase
polymorphisms in lung cancer risk. Cancer Epidemiology, Biomarkers and
Prevention 2000; 9:1017-20.
Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect
of insulin-like growth factors and mutagen sensitivity in lung cancer
risk. Growth Hormone & IGF Research
2000; Suppl A:S26-7.
Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu
X. Genetic variants of myeloperoxidase
and lung cancer risk. Carcinogenesis
2000; 21(6):1163-6.
Wu X, Yu H, Amos
CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen
sensitivity in lung cancer risk. Journal of the National
Cancer Institute 2000; 92(9):737-43.
Vulimiri SV, Wu X,
Baer-Dubowska W, de Andrade M, Detry M, Spitz MR, DiGiovanni J. Analysis of aromatic DNA adducts and
7,8-dihydro-8-oxo-2’-deoxyguanosine in lymphocyte DNA from a case-control study
of lung cancer involving minority populations. Mol Car 2000; 27:34-46.
Spitz MR, Detry
MA, Pillow P, Hu Y, Amos CI, Hong WK, Wu, X. Variant alleles of the D2 dopamine
receptor gene and obesity. Nutrition Research 2000; 20(3):371-380.
Abdel-Rahman SZ, Soliman AS, Bondy ML, Wu X,
El-Badawy SA, Mahgoub KG, Ismail S, Seifeldin IA, Levin B. Polymorphism of glutathione S-transferase loci GSTM1 and GSTT1
and susceptibility to colorectal cancer in Egypt. Cancer Letters 1999;
142:97-104.
Gu J, Spitz MR, Yang F, Wu X. Ethnic differences in poly (ADP-ribose)
polymerase pseudogene genotype distribution and association with lung cancer
risk. Carcinogenesis 1999; 20(8):1465-9.
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth
factor-I and lung cancer risk: a case-control analysis. Journal
of the National Cancer Institute 1999; 91(2):151-6.
Gu J, Bondy ML, Sigurdson A, Spitz MR, Hsu TC, Wu
X. Three measures of mutagen
sensitivity in a cancer-free population.
Cancer Genetics and Cytogenetics 1999; 110:65-9.
Wu X, Kemp B, Amos CI, Honn SE, Zhang W, Walsh GL,
Spitz MR. Associations among telomerase activity, p53 protein overexpression,
and genetic instability in lung cancer.
British Journal of Cancer 1999; 80:453-7.
Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL,
Wu X, Chan W, Pershouse MA, Yung WKA, Steck PA. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas:
relationship to prognostic significance. Clinical Cancer Research 1998;
4:2447-54.
Wu X, Zhao Y, Kemp BL, Amos CI, Siciliano MJ, Spitz
MR. Chromosome 5 aberrations and genetic predisposition to lung cancer.
International Journal of Cancer 1998; 79:490-3.
Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, Winn
RJ, Fu KK, Cooper J, Spitz MR. Benzo[a]pyrene diol epoxide and bleomycin
sensitivity and susceptibility to cancer of upper aerodigestive tract. Journal
of the National Cancer Institute 1998; 90(18):1393-9.
Wu X, Gu J, Amos CI, Jiang H, Hong WK, Spitz MR. A
parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and
bleomycin in lung carcinoma cases and controls. Cancer 1998; 83:1118-27.
Wu X, Zhao Y, Honn SE, Tomlinson GE, Minna JD, Hong
WK, Spitz MR. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and
genetic predisposition to lung cancer.
Cancer Research 1998; 58:1605-8.
Wu X, Gu J, Patt Y, Hassan M, Spitz MR, Beasley RP,
Hwang LY. Mutagen sensitivity as a
susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiology, Biomarkers and
Prevention 1998; 7:567-70.
Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H,
Chamberlain RM, Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X. A case-control study of the D2 dopamine
receptor gene and smoking status in lung cancer patients. Journal of the National Cancer Institute
1998; 90:358-63.
Wu X, Hsu TC, Cao S, Lee JJ, Amos CI, Spitz MR.
Deletion in poly(ADP-ribose) polymerase pseudogene and lung cancer risk.
Carcinogenesis 1998; 19(1):93-8.
Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, Spitz
MR Cytochrome P450 2E1 DraI
polymorphisms in lung cancer in minority populations. Cancer Epidemiology, Biomarkers and Prevention 1998; 7:13-8.
Wu X, Dave BJ, Jiang H, Pathak S, Spitz MR. Lung
carcinoma patients with a family history of cancer and lymphocyte primary
chromosome 9 aberrations. Cancer 1997;
79:1527-32.
King TM, Trizna Z, Wu X, Amos CI, Fueger RH, Fueger JJ,
Fritsche HA, Hsu TC, Winn R, Spitz MR. A clinical trial to evaluate the effect
of vitamin C supplementation on in Vitro mutagen sensitivity. Cancer Epidemiology, Biomarkers and
Prevention 1997; 6:537-42.
Wu X, Hsu TC, Spitz MR. Mutagen sensitivity exhibits
a dose-response relationship in case-control Studies. Cancer Epi Bio & Prev 1996; 5:577-8.
Spitz MR, Wu X, Jiang H, Hsu TC. Mutagen sensitivity as a marker of cancer susceptibility. Journal of Cellular Biochemistry 1996;
25S:80-4.
Wu XF, Spitz MR, Delclos GL, Connor TH, Zhao Y, Siciliano
MJ, Hsu TC. Survival of cells with
bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung
cancer patients. Cancer Epidemiology,
Biomarkers and Prevention 1996; 5:527-32.
Hsu TC, Wu X, Trizna Z. Mutagen sensitivity in humans: A comparison between two
nomenclature systems for recording chromatid breaks. Cancer Genetics and Cytogenetics 1996; 87:127-32.
Wu X, Hsu TC, Annegers JF, Amos CI, Fueger JJ, Spitz
MR. A case-control study of nonrandom distribution of bleomycin-induced
chromatid breaks in lymphocytes of lung cancer cases. Cancer Research 1995; 55:557-61.
Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth
JA. Mutagen sensitivity as a biologic
marker of lung cancer risk in African Americans. Cancer Epidemiology, Biomarkers and Prevention 1995; 4:99-103.
Wu X, Delclos GL, Annegers JF, Bondy ML, Honn SE,
Henry B, Hsu TC, Spitz MR. A case-control study of wood-dust exposure, mutagen
sensitivity, and lung-cancer risk.
Cancer Epidemiology, Biomarkers and Prevention 1995; 4:583-8.
Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C,
Honn SE, Spitz MR. Higher lung-cancer
risk for younger African Americans with the Pro/Pro p53 genotype.
Carcinogenesis 1995; 16(9):2205-8.
Strom SS, Wu X, Sigurdson AJ, Hsu TC, Fueger JJ,
Lopez J, Tee PG, Spitz MR. Lung cancer, smoking patterns, and mutagen sensitivity
in Mexican-Americans. Journal of the National Cancer Institute (Monograph)
1995; 18:29-33.
Wu X, Zhang QF.
A review on the combined effects of mixed dusts. J Labor Med 1990; 7:45-7 (in Chinese).
Wu X, He LR, Hong CF. Preventive efficacy of a
Chinese traditional medicine anti-silicosis tablet on silicosis. 1990; Zhejiang
Acad Med Sci.
Wu X, Hong CF. Application of the method of
measuring cellular ATP on the research of pneumoconiosis. J Occ Med 1990; 17:231-2.
Wu X, Zhang QF. The effect of zinc on the alveolar
macrophage cytotoxicity due to nickel-coal dust. Chinese Med J 1990; 103:754-8.